One-year survival rates for patients receiving heart, liver and lung transplants at UCSF Medical Center exceed national averages at statistically significant levels, according to new data compiled by the Scientific Registry of Transplant Recipients (SRTR).

Released on January 11, the report measures performance and characteristics of each transplant program at all facilities in the United States, including waiting list outcomes, post-transplant survival rates, and organ recovery and transplantation rates. Reported statistics can be found on the SRTR website (www.ustransplant.org).

John P. Roberts, MD. (Photo Credit: UCSF Photo)

“The registry collects data from the nation’s transplant programs and uses an algorithm they created to standardize calculations across facilities, looking at such information as how sick patients are in each program and then assigning an expected survival rate,” explained John P. Roberts, MD, chief of the UCSF Medical Center Transplant Service.

According to the report, the one-year survival rate for the UCSF Heart Transplant Program was 100 percent, compared to an expected survival rate of 87 percent. The UCSF Liver Transplant Program produced a one-year survival rate of 92 percent compared to an expected 88 percent, and the Lung Transplant Program generated a one-year survival rate of 90 percent compared to an expected 80 percent. The expected survival rates reflect the health condition of each program’s transplant patients.

UCSF is recognized for tackling the most complex transplant surgeries, including multiple organ transplants, and is the only hospital among the U.S. News & World Report top 18 hospitals with these three programs that exceeds the national averages for expected survival rates at significant levels.

UCSF transplant teams include a full range of patient care and support personnel, and all are committed to achieving better-than-expected survival rates, according to Roberts and also emphasized by Teresa De Marco, MD, medical director of the UCSF Heart Transplant Program.

Many audiences, such as patients and families looking to select a transplant program, use the SRTR data. Transplant surgeons use it to explain a patient’s prospects for recovery, as do administrators addressing quality control for transplant programs, insurance companies and payers, and federal regulatory bodies charged with protecting patients.

Transplants are the most advanced treatment for patients with severe, end-stage disease with no other effective, available medical or surgical treatments, according to clinicians.